Inventiva Announces That Its Partner Sino Biopharm Received IND Approval From The NMPA To Initiate Clinical Trial With Lanifibranor In China
Portfolio Pulse from Happy Mohamed
Inventiva's partner Sino Biopharm has received IND approval from the NMPA to initiate clinical trials with lanifibranor in China. This will allow the clinical development of Inventiva's lead compound in mainland China, and Inventiva is now eligible for the first of two short-term milestones amounting to a total of $5 million.
May 25, 2023 | 8:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inventiva's partner Sino Biopharm received IND approval to initiate clinical trials with lanifibranor in China, making Inventiva eligible for $5 million in milestones.
The IND approval allows Inventiva's lead compound to advance into a Phase III clinical trial in NASH in mainland China. This is an important milestone for Inventiva and its partner Sino Biopharm, as it brings new opportunities for patients affected by NASH in China to participate in the global NATiV3 Phase III clinical trial. The approval also makes Inventiva eligible for the first of two short-term milestones amounting to a total of $5 million, which is a positive development for the company and its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100